Navigation Links
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
Date:5/3/2011

oking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031, LX1032, LX1033, LX2931, and LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.Lexicon Pharmaceuticals, Inc.Selected Financial DataConsolidated Statements of Operations DataThree Months EndedMarch 31,(In thousands, except per share data)20112010(unaudited)Revenues:Collaborative research$  516$  1,641Subscription and license fees80-Total revenues5961,641Operating expenses:Research and development, inclu
'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Lexicon to Provide First Quarter 2011 Financial Results
2. Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
3. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
5. Lexicon to Report Fourth Quarter and Year End 2010 Financial Results on February 24, 2011
6. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
7. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
8. Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
9. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
10. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
11. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)...   Plexus Information Systems, Inc. (Plexus ... Systems (AIMS), announced a partnership with NextGen ... subsidiary of Quality Systems, Inc. and a leading ... Logo - http://photos.prnewswire.com/prnh/20140930/149406 ... This partnership extends the NextGen Healthcare product portfolio ...
(Date:10/1/2014)... NeuroCall, Inc., ("NeuroCall") announced today that it ... Teleneurology services. Dr. Ricardo Garcia-Rivera , Founder and ... proud that our quality of service has been recognized ... lifesaving support and continuity of care to patients of ... the United States ." NeuroCall ...
(Date:10/1/2014)... Oct. 1, 2014 Quantum Materials Corp ... production of photoactive quantum dots for use in ... offering numerous advantages for solar power generation, the ... of quantum dots with which to develop thin ... from commercial utilization and acceptance. The company is ...
Breaking Medicine Technology:Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3NeuroCall Awarded Joint Commission Accreditation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3
... Every Four-Week Subcutaneous Golimumab Also Experienced ... and Disease Activity, PARIS, June 11 Findings ... every four-week subcutaneous injections of,golimumab (CNTO 148) 50 mg ... in the signs and symptoms of,rheumatoid arthritis (RA) as ...
... maintenance ... compared to placebo, BRIDGEWATER, N.J., June 10 Sanofi-aventis,announced ... (zolpidem,tartrate extended-release) CIV tablets 12.5 mg provided significant,improvement in sleep ... patients with co-morbid insomnia and major depressive disorder,(MDD) who were ...
Cached Medicine Technology:Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 2Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 3Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 4Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 5Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 6Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 7Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 8Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder 2Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder 3Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder 4Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder 5
(Date:10/1/2014)... (PRWEB) October 01, 2014 Familylifeinsurancequotes.org ... find life insurance for senior citizens. , Senior ... Agencies will now sell coverage to seniors who are ... can be purchased without taking a medical examination. , ... purchased online and senior clients can qualify. Having life ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post ... for smokers. , Smoking will always have a negative ... the best method to find affordable coverage. Insurance brokerage ... coverage. , Whole life insurance premiums will be ... the coverage is permanent, the initial rates are ...
(Date:10/1/2014)... 01, 2014 Farmington Company today ... redefined mission and visual identity helping brokers, consultants ... with them to create greater benefit communication synergies. ... focuses on empowering customers to better leverage Farmington ... crown jewel of the rebrand is the refreshed ...
(Date:10/1/2014)... 2014 Between 23 million and 50 ... according to figures from the National Institutes of Health ... and many of them have something else in common: ... celiac disease. Gluten Free Therapeutics, makers of CeliVites ... celiac disease by publishing a series of blog posts ...
(Date:10/1/2014)... Toronto, Canada (PRWEB) October 01, 2014 ... hair removal and skin rejuvenating destination of choice, is ... run from October through to December. , “We’re doing ... access as possible to our top skin clinic in ... Clinic. “We do so much at Anti Aging Clinic, ...
Breaking Medicine News(10 mins):Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2
... LANCASTER, Pa., June 12 Herley Industries,Inc. (Nasdaq: ... third quarter,ended May 4, 2008. Herley reported net sales ... or 13% from the third quarter of the prior,fiscal ... of $0.27 per share including,the impact of a litigation ...
... allow physicians to more accurately diagnose and treat ... University to Syntermed, an Atlanta-based nuclear medicine imaging ... phase analysis (MHPA), a technology developed by Emory ... PhD. , MHPA is designed to quickly and ...
... and molecular machinery is pointing toward new drugs and ... emerging era of personalized medicine, in which doctors aim ... for the right patient, also brings concerns about genetic ... , The American Association for the Advancement of ...
... TULSA, Okla., June 12 Do you know ... those individuals and,organizations working to improve Oklahoma,s health. ... of those who are making a,significant difference in ... the deadline of Friday, Aug. 1., Nominations ...
... Clear Need for Continued Industry Commitment to Health IT Privacy and ... ... June 12 As consumer options for online,health management expand, there ... complex technologies contribute to,better health and added convenience. Wide-spread adoption requires ...
... June 12 Best Practices, LLC,conducted this study ... used by companies across various industries to measure,the ... pharmaceutical industry, number of sales calls is most ... manufacturing,companies employ year over year account revenue growth ...
Cached Medicine News:Health News:Herley Reports Third Quarter Results 2Health News:Herley Reports Third Quarter Results 3Health News:Herley Reports Third Quarter Results 4Health News:Herley Reports Third Quarter Results 5Health News:Herley Reports Third Quarter Results 6Health News:Herley Reports Third Quarter Results 7Health News:Herley Reports Third Quarter Results 8Health News:Herley Reports Third Quarter Results 9Health News:Herley Reports Third Quarter Results 10Health News:Herley Reports Third Quarter Results 11Health News:Herley Reports Third Quarter Results 12Health News:Herley Reports Third Quarter Results 13Health News:Syntermed licenses Emory imaging technology for improved evaluation of heart failure patients 2Health News:AAAS hosts June 20 conference on personalized medicine 2Health News:Nominations Accepted for 2008 'Champions of Health' Awards 2Health News:More Americans Aware of Digital Health Options; Use of Health IT Increases 2Health News:More Americans Aware of Digital Health Options; Use of Health IT Increases 3Health News:More Americans Aware of Digital Health Options; Use of Health IT Increases 4Health News:Benchmarking Study Report on Sales Performance Management 2
... Agilis Steerable Introducer helps physicians ... right or left atrium. With ... tip, and radiopaque tip marker, ... the agility and stability needed ...
... 70 RF Generator introduces maximum ... every day, in every ablation ... and the CARTO EP Navigation ... Catheter provide clinicians with a ...
The Microny pacemakers are among the smallest devices in the world. The Microny II SR+ pacemaker is the world's smallest, single-chamber rate-responsive pulse generator. The Microny pacemakers featur...
... family of pacemakers features several ... truly automatic devices in today's ... unparalleled combination of automated features ... builds on the popular and ...
Medicine Products: